Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps
Incyte’s Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2’s primary endpoint fell short. Latest Ratings for INCY Date Firm Action From To Feb 2022 SVB Leerink Downgrades Market Perform Underperform Feb 2022 Morgan Stanley Maintains Equal-Weight Jan 2022 RBC Capital Upgrades Sector Perform Outperform View More Analyst Ratings…
Freshpet Is Not Out Of The Woods On Consumption Trends, Analyst Says
JP Morgan analyst cuts Freshpet price forecast to $102 while maintaining a Neutral rating. Concerns over changing consumption trends and accuracy of estimates, but strong revenue growth and long-term potential. EBITDA and revenue growth estimates revised. Latest Ratings for FRPT Date Firm Action From To Dec 2021 Citigroup Maintains Sell Dec 2021 Credit Suisse Maintains…
Apple Supplier Foxconn Unveils AI Model Using Nvidia Tech
Foxconn built AI model FoxBrain in 4 weeks with reasoning capabilities, aiming to advance manufacturing and supply chain management. read more
Bloomin’ Brands Is A Long-Term Survivor, But Has Near-Term Challenges: Analyst
JP Morgan analyst lowers price forecast for Bloomin’ Brands from $13 to $10, retains Neutral rating. Challenges ahead, but potential for success. Latest Ratings for BLMN Date Firm Action From To Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Deutsche Bank Maintains Buy Feb 2022 BMO Capital Maintains Outperform View More Analyst Ratings for BLMN…
Oracle Stock Stumbles Into Q3 Earnings: Will Buyers Step In As It Nears Oversold Territory
Oracle Corp reports Q3 earnings on Monday. Stock currently in strongly bearish trend, but oversold conditions may present long-term opportunity. read more
